Deletion at 6q24.2–26 predicts longer survival of high‐grade serous epithelial ovarian cancer patients
Open Access
- 5 October 2014
- journal article
- Published by Wiley in Molecular Oncology
- Vol. 9 (2) , 422-436
Abstract
Standard treatments for advanced high‐grade serous ovarian carcinomas (HGSOCs) show significant side‐effects and provide only short‐term survival benefits due to disease recurrence. Thus, identification of novel prognostic and predictive biomarkers is urgently needed. We have used 42 paraffin‐embedded HGSOCs, to evaluate the utility of DNA copy number alterations, as potential predictors of clinical outcome. Copy number‐based unsupervised clustering stratified HGSOCs into two clusters of different immunohistopathological features and survival outcome (HR = 0.15, 95%CI = 0.03–0.81; Padj = 0.03). We found that loss at 6q24.2–26 was significantly associated with the cluster of longer survival independently from other confounding factors (HR = 0.06, 95%CI = 0.01–0.43, Padj = 0.005). The prognostic value of this deletion was validated in two independent series, one consisting of 36 HGSOCs analyzed by fluorescent in situ hybridization (P = 0.04) and another comprised of 411 HGSOCs from the Cancer Genome Atlas study (TCGA) (HR = 0.67, 95%CI = 0.48–0.93, Padj = 0.019). In addition, we confirmed the association of low expression of the genes from the region with longer survival in 799 HGSOCs (HR = 0.74, 95%CI = 0.61–0.90, log‐rank P = 0.002) and 675 high‐FIGO stage HGSOCs (HR = 0.76, 95%CI = 0.61–0.96, log‐rank P = 0.02) available from the online tool KM‐plotter. Finally, by integrating copy number, RNAseq and survival data of 296 HGSOCs from TCGA we propose a few candidate genes that can potentially explain the association. Altogether our findings indicate that the 6q24.2–26 deletion is an independent marker of favorable outcome in HGSOCs with potential clinical value as it can be analyzed by FISH on tumor sections and guide the selection of patients towards more conservative therapeutic strategies in order to reduce side‐effects and improve quality of life.Keywords
Funding Information
- Fondo de Investigación Sanitaria (PS09/01094)
- Instituto de Salud Carlos III (PI12/01319)
- Ministerio Español de Sanidad y Consumo (13/00047)
- Fundación La Caixa (BIO2012-40205)
- Red Temática de Investigación Cooperativa en Cáncer (RD12/0036/0028, RD12/0036/0037, RD12/0036/0064)
This publication has 65 references indexed in Scilit:
- Disruption of TTDA Results in Complete Nucleotide Excision Repair Deficiency and Embryonic LethalityPLOS Genetics, 2013
- Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment OutcomeClinical Cancer Research, 2012
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupJournal of Clinical Oncology, 2012
- Histone acetylation by CBP and p300 at double-strand break sites facilitates SWI/SNF chromatin remodeling and the recruitment of non-homologous end joining factorsOncogene, 2011
- ARID1AMutations in Endometriosis-Associated Ovarian CarcinomasNew England Journal of Medicine, 2010
- Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancerMolecular Carcinogenesis, 2008
- Correlation between 6q25.3 deletion status and survival in pediatric intracranial ependymomasCancer Genetics and Cytogenetics, 2008
- Cyclin D1, p53, and p21Waf1/Cip1 Expression Is Predictive of Poor Clinical Outcome in Serous Epithelial Ovarian CancerClinical Cancer Research, 2004
- Genomic Aberrations and Survival in Cutaneous T Cell LymphomasJournal of Investigative Dermatology, 2004
- Expression of c‐ABL, c‐KIT, and platelet‐derived growth factor receptor‐β in ovarian serous carcinoma and normal ovarian surface epitheliumCancer, 2003